Lobarstin PTP-1b Inhibitor Selectivity Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes and obesity, particularly targeting insulin resistance and PTP-1b inhibition, face challenges with low selectivity and bioavailability of developed compounds, and existing methods do not effectively address the increasing prevalence of these conditions.
Innovation Solution
A novel compound, Lobarstin, synthesized from an extract of Stereocaulon alpinum, is developed, which is water-soluble and selectively inhibits PTP-1b, offering improved antidiabetic and anti-obesity effects by enhancing insulin sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional compounds are used to treat diabetes and obesity, then insulin resistance can be addressed, but the compounds have low selectivity and poor bioavailability
Solution Approach 1:
The patent modifies the chemical structure of lobaric acid by converting the carboxylic acid group to a methyl ester group, creating lobarstin. This structural parameter change improves both selectivity for PTP-1b inhibition and bioavailability compared to the parent compound lobaric acid, resolving the contradiction between selective action and adequate substance availability in the body
2Productivity
If the number of diabetic patients increases due to economic development and lifestyle changes, then medical expenses increase, but effective treatment options remain limited
Solution Approach 1:
The patent extracts and isolates the active compound lobarstin from the Antarctic lichen Stereocaulon alpinum through systematic extraction and purification processes. This extraction of the specific active ingredient from the natural source creates a standardized, effective treatment that can be applied broadly to address the growing diabetic population without requiring complex treatment protocols
3Reliability
If PTP-1b inhibition is targeted to improve insulin sensitivity, then antidiabetic effects are achieved, but existing inhibitors have low selectivity among protein tyrosine phosphatases
Solution Approach 1:
The patent achieves local quality enhancement by designing lobarstin to specifically interact with the active site of PTP-1b through its modified ester group. This localized molecular interaction provides high selectivity for PTP-1b over other protein tyrosine phosphatases, ensuring that the antidiabetic effect is achieved without off-target effects on other phosphatases
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to pharmaceutical and food compositions for preventing or treating diabetes or obesity, and more particularly to pharmaceutical compositions and functional foods for preventing or treating diabetes or obesity, which contain, as an active ingredient, a novel compound synthesized from a compound separated from an extract of the Stereocaulon alpinum. The novel compounds of the invention have very excellent PTP-1b (protein tyrosine phosphatase-1b) inhibitory activities, act selectively only on PTP-1b among protein tyrosine phosphatases, and are substantial PTP-1b inhibitors which are effective in preventing or treating diabetes or obesity.